Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression.


BACKGROUND The development of neutralizing alloantibodies (inhibitors) is the most serious complication of factor VIII (FVIII) replacement therapy in patients with hemophilia A. Unlike previously untreated patients, no definite risk factors for inhibitor development are known for previously treated patients (PTPs). The investigation of the development of… (More)
DOI: 10.1111/jth.12335


  • Presentations referencing similar topics